25 February 2021 - Exelixis expects to submit supplementary New Drug Application in 2021.
Exelixis today announced that the U.S. FDA has granted breakthrough therapy designation to cabozantinib (Cabometyx) as a potential treatment for patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).